cyrilzakka/clinical-trials huggingface dataset:
Epidemiology of Bunion and Risk Factors

Analysis of the collected data to determine:

* Prevalence.
* Risk factors. Radiological and clinical patterns and their association with specific risk factors Of Hallux Valgus

Hallux valgus (HV) is a common foot deformity whose multifactorial and complex and associated with other foot deformities. It is a common 1st ray deformity characterized by excessive angulation, rotation, and lateral deviation of the great toe at the first metatarsophalangeal joint . There are many symptoms of HV include poor fitting shoes, plantar foot pain, and pain in the medial first MTP joint .The resultant deformity causes pain and discomfort, which decreases the physical function of the foot and has been identified as a risk factor for falls in older people . Systematic reviews estimated the prevalence of HV to be more frequent with Old age and is more prevalent in women . Several risk factors for HV have been identified HV is associates with wearing high-heeled or narrow shoes . Foot problems are prevalent in old aged and are thought to be associated with high heels and narrow shoes The relationship between HV and obesity is less clear. Some studies have found an association between HV and increasing body mass index whereas others have found no association. Most recently, it has been suggested that the association between HV and BMI differs between the genders, with a lower prevalence with increasing BMI in women but no association in men and in Upper Egypt the principle investigator aim to collect data through a cross sectional study to know the prevalence and calculate the percentage of each certain risk factor through AP Standing Foot and evaluate HV angles and determind who has HV and then calaculate the prevalence and determind associated Risk Factors , while collecting cases the principle investigator focus on Emergency Unit on people without Foot Trauma , no neurological deficit and from outpatient clinic

Eligibility Criteria:
Inclusion Criteria:

* aged (18 - 80) including both sexes Males and Females
* Patients with no Foot trauma or Neurological deficit

Exclusion Criteria:

1. Post traumatic Hallux valgus
2. post infection Hallux valgus
3. Post Surgical Hallux valgus -
Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy

This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Injury of the optic nerve or optic neuropathy is one of the most common causes of vision loss. This study aimed to investigate the therapeutic effect of subcutaneous erythropoietin in the management of late stage optic neuropathy.

Eligibility Criteria:
Inclusion Criteria:

* Patients with late stage optic neuropathy (1 month to 12 months after onset of optic neuropathy due to late referral of the cases)

Exclusion Criteria:

* Patients with perforating ocular injuries were excluded.
Reassure Spot Respiration Rate Accuracy Compared to SOMNOScreen

A trial conducted within the company with a new non-contact respiration rate (RR) sensor. The device was compared for accuracy in RR measurement with a cleared device, the SOMNOScreen Easy, which uses chest effort bands.

The RR was measured over a short duration on subjects sitting upright in a chair, with the non-contact sensor at various distances from the subject. A total of 20 subjects were tested, from both genders, selected to represent a wide range of age and body mass index

The Reassure uses Radio Frequency (RF) waves to detect the small movements of the human body due to respiration. The reference device, the SOMNOScreen, uses chest effort bands. The Reassure is non-contact and so more comfortable and convenient for quick RR measurement, in a similar way that an Infra-Red thermometer is compared to a traditional under-the-tongue mercury thermometer.

The aim is to explore the variations in the human body that could have an effect on the radio reflection from the human torso, and thus affect the potential detection and accuracy of breathing rate. Factors that could affect non-contact RF performance are:

* High Body Mass Index (BMI) could potentially reduce the chest wall movement during breathing, or alter the nature of the breathing.
* Elderly, thin skin (ie pensioner with low BMI) may have less RF reflection.
* Female breast tissue may have an effect on detection or accuracy.

This was tested at a number of distances from the non-contact sensor and also with the subject having a thick comforter (duvet) laid across them.

The test conditions were

* Distances of 0.5 m, 1.0m and 1.5m between the subject and the RF sensor.
* Additional test condition of comforter (duvet) on the subject when the distance from subject to sensor is 1.0 m.
* Each test condition carried out twice.

The use of the comforter in one test condition is to confirm that the RR measurement by the Reassure is unaffected by the thickness of clothing or blankets being worn.

Eligibility Criteria:
Inclusion Criteria:

* Greater or equal to 18 years old and less than or equal to 75 years old
* BMI within the range of greater or equal to 18 and less than or equal to 45
MIDCAB Versus DES in Proximal LAD Lesions

Percutaneous coronary intervention with a sirolimus-coated stent compared to minimally invasive bypass surgery in patients with isolated proximal left anterior descending coronary arteries in terms of non-inferiority of an end point combining mortality, acute myocardial infarction and rate of reintervention of the target vessel within one year.


Eligibility Criteria:
Inclusion Criteria:

1. Single-vessel disease of the proximal LAD with a stenosis \> 50% (multivessel disease only if further coronary vessel stenoses do not require treatment)
2. Patients with angina pectoris (CCS 1-4)
3. Asymptomatic patients if clear signs of ischemia in the segments supplied by the LAD as assessed by bicycle ergometry or treadmill and/or scintigraphically and/or stress echo
4. Patients for whom both methods of treatment are equally possible
5. Consensus between the cardiac surgeon and the cardiologist that both inclusion and exclusion criteria are met in the selected case
6. Informed consent of the patient.

Exclusion Criteria:

1. Patients \< 18 years
2. Pregnancy
3. Previous coronary artery bypass surgery
4. Concomitant diseases that lead to a greater risk for each of the treatment strategies
5. Significant peripheral arterial occlusive disease
6. Concomitant disease with limited life expectancy (e.g. malignant tumours that have not been curatively treated)
7. Objective follow-up examination not possible due to physical or mental handicap
8. Participation in another study.

Angiographical exclusion criteria:

1. Left main stem stenosis
2. Multivessel disease for which surgical or interventional therapy on other vessel areas is required.
3. Diagonal/septal branch \> 1.5 mm, which might be compromised by a stent
4. Need for acute intervention (e.g. acute myocardial infarction)
5. Total occlusion of the LAD
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.


Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

* Healthy participants as determined by no clinically significant deviation from normal in medical history, physical exam, ECGs, and clinical laboratory determinations
* Weight within the range of ≥60 and ≤90 kg
* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug
* WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with BMS-986263 (21 days), plus 5 half-lives of BMS-986263 (7.5 days) plus 30 days (duration of ovulatory cycle) for a total of 90 days post-treatment completion
* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of treatment with BMS-986263 (21 days) plus 5 half-lives of BMS-986263 (7.5 days) plus the duration of sperm turnover (90 days) for a total of 118.5 days post-treatment completion. In addition, male participants must be willing to refrain from sperm donation during this time. Azoospermic males are exempt from contraceptive requirements

Exclusion Criteria:

* History or evidence of active infection and/or febrile illness within 7 days of Study Day 1 (e.g., bronchopulmonary, urinary, gastrointestinal, etc.)
* History of serious bacterial, fungal, or viral infections that let to hospitalization and IV antibiotic treatment within 90 days prior to screening, or any recent serious infection requiring antibiotic treatment within 30 days of Study Day 1
* History of recurrent or chronic sinusitis, bronchitis, pneumonia, urinary tract infection, or skin infection (recurrent or chronic infection is defined as ≥2 episodes within a 6 month period)
* Active herpes infection, including herpes simplex 1 and 2 and herpes zoster (demonstrated on physical examination and/or medical history)
* History of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
* Presence of active tuberculosis (TB), latent TB, or inadequately treated latent or active TB

Other protocol defined inclusion/exclusion criteria could apply
Dreams or Implicite Memorization Under OFA

The Dreams study is an observational study aimed at evaluating the incidence of connected awareness after intubation, intraoperative explicit and implicit memorization, and postoperative well-being in patients receiving general anesthesia without opioids.

Outcomes

The primary objective is the evaluation of the incidence of connected consciousness after induction of general anesthesia without opioids and intubation. The secondary objectives are:

* Implicit and explicit memorization after intubation and during the procedure
* Post-operative well-being Pain in the recovery room and in the room, assessed by VAS;
* Total consumption of analgesics (paracetamol, diclofenac, tramadol): data collected during discharge
* Level of satisfaction, assessed using the EVAN scale
* Duration of hospitalization
* Estimated first mobilization


Eligibility Criteria:
Inclusion Criteria:

* laparoscopic robotic surgery
* ASA score 1 to 3

Exclusion Criteria:

* neurological and psychiatric diseases
* reflect memory disorders
* head trauma
* hearing disorders
* past or current use of medications affecting the central nervous system.
Computer Guided Contouring of Craniofacial Fibrous Dysplasia Involving Zygoma

This study will be conducted on patients with monostotic unilateral craniofacial fibrous dysplasia affecting zone I (fronto-orbital, zygomatic, and upper maxillary regions). Computer guided shaving will be performed for all the patients, and the accuracy of this procedure will be assessed.

This study will be conducted on patients with monostotic unilateral craniofacial fibrous dysplasia affecting zone I (fronto-orbital, zygomatic, and upper maxillary regions).

I. Preoperative preparation

1. Virtual planning Computed tomography (CT) will be performed for the skull using a multi-slice helical CT machine. Computed tomography DICOM (digital Imaging and Communication in Medicine) files will be imported to the 3D surgical planning software (Mimics 10.0, Materialise NV, Leuven, Belgium). Using the software and through a series of segmentation and simulation processes, area of interest will be virtually selected and separated. Finally, the virtual image of the surgical guide will be reconstructed.
2. Rapid prototyping Stereolithographic (STL) files of the virtual image will be exported to multi-jet modelling printing machine (InVision Si2, 3D Systems e Rock Hill, SC) and will be fabricated using plastic material (VisiJet SR 200, 3D Systems e Rock Hill, SC).

II. Surgical procedures Area of interest for all patients will be exposed using the hemicoronal, and maxillary intraoral vestibular incisions. The surgical guide(s) will be seated in position on the affected side. Bone removal will be performed through the guide according to the preoperative planning. The bone removal will be then performed to connect the guiding holes using surgical burs. Finally, the incisions will be sutured after soft tissue suspension.

III. Follow up Postoperative CT will be performed for postoperative assessment. After 1 week patients will be recalled for suture removal and clinical assessment. Then the patients will be recalled 1, 3 months for further assessment.

Eligibility Criteria:
Inclusion Criteria:

* Monostotic unilateral craniofacial fibrous dysplasia.
* Facial asymmetry affecting zone I (fronto-orbital, zygomatic, and upper maxillary regions)
* More than 17 years

Exclusion Criteria:

* functional deficits
* orbital manifestations
ESP Block for Postoperative Analgesia in URS Surgery

The goal of this clinical trial is to determine whether the erector spinae plane (ESP) block provides better pain relief after flexible ureterorenoscopy (URS) surgery compared to standard analgesia alone. Researchers want to know:

Does the ESP block reduce pain levels in the first 24 hours after surgery?

Does it lower the need for opioid pain medication?

Does it reduce the need for additional (rescue) pain treatment?

Does it decrease the likelihood of postoperative nausea and vomiting (PONV)?

Participants will be randomly placed into one of two groups:

ESP Block Group: Participants will receive an ESP block using 20 mL of 0.25% bupivacaine under ultrasound guidance before surgery.

Control Group: Participants will receive standard pain management without a nerve block.

All participants will receive general anesthesia during surgery and multimodal pain management after surgery. Researchers will compare pain scores, opioid use, rescue analgesic needs, and the occurrence of nausea and vomiting between the two groups.

Intervention Group (ESP Block): Patients will receive 20 mL of 0.25% bupivacaine (1:1 diluted with 0.5% bupivacaine) under ultrasound guidance at the T8-T10 level.

Control Group: No block will be performed, and patients will receive standard postoperative multimodal analgesia.

Procedure Description: The ESP block will be performed under sterile conditions with a high-frequency linear ultrasound probe. A 100-mm echogenic needle will be inserted in a cephalocaudal direction to deposit the local anesthetic deep to the erector spinae muscle at the transverse process level. The correct spread of the anesthetic will be confirmed via real-time ultrasound imaging.

All patients will receive standardized general anesthesia and multimodal analgesia.

Outcome measures include postoperative pain (NRS), opioid consumption, rescue analgesia requirement, and postoperative nausea and vomiting (PONV).

Eligibility Criteria:
Inclusion Criteria:

Patients undergoing elective flexible ureterorenoscopy (URS).

Age: 18-65 years.

ASA I-II.

Willing to participate and provide written informed consent.

Exclusion Criteria:

BMI \>35 kg/m².

Allergy to local anesthetics.

Coagulation disorders or use of anticoagulants.

Patients requiring emergency surgery.

Patients with infection at the ESP block site.
Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics

To assess the safety of long-term use of cetirizine dry syrup in children with various type of cutaneous disease accompanied on pruritus.


Eligibility Criteria:
Inclusion Criteria:

* Chronic urticaria
* Eczema \& dermatitis group
* Atopic dermatitis
* Prurigo group: Acute prurigo, Prurigo subacuta, Chronic prurigo
* Pruritus cutaneous: Systemic pruritus cutaneous, Topical pruritus cutaneous
* Giving informed consent
* Children who have 2 grades or more pruritus score when assessed by the investigator or sub-investigator with the criteria for the diurnal or nocturnal pruritus score in the patient diary.
* Children with a pruritus severity of "2.Mild" or severer on the first day of the treatment period.

Exclusion criteria:

* have a history of drug hypersensitivity
* are pregnant, lactating or possibly pregnant female children.
* have asthma that requires the treatment with corticosteroid.
* cannot avoid the use of external steroid classified into "strong", "strongest" or "very strong".
* have pruritus only on face and head.
* have inappropriate complication of dermal disorder that may influence on the evaluation of the study drug.
* are undergoing specific desensitization therapy or immunomodulation therapy or phototherapy.
Disruptions of Brain Networks and Sleep by Electroconvulsive Therapy

Electroconvulsive therapy (ECT) alleviates treatment-resistant depression (TRD) through repeated generalized seizures. The goal of this study is to evaluate how ECT impacts sleep-wake regulation and efficiency of information transfer in functional networks in different states of arousal.

Graph-based network analyses of electroencephalographic (EEG) signals allow characterization of functional networks. The robustness of local networks to disruption is quantified as local efficiency (Elocal), while network integration is quantified as global information transfer (Eglobal).

Aim 1: Assess relationships between sleep slow-wave activity (SWA) and awake Elocal over the course of ECT.

Aim 2: Quantify relationships between depression severity and awake Elocal over the course of ECT.

Eligibility Criteria:
Inclusion Criteria:

* Referral for initial ECT index course for Treatment-Resistant Depression (TRD), unipolar major depressive disorder or bipolar depression. Historic failure of response or remission to at least two antidepressant medications of sufficient dose and duration will be used for TRD diagnostic.

Exclusion Criteria:

* Diagnoses of schizophrenia or schizoaffective disorders.
* Subjects who are unable to tolerate the Dreem device for sleep recordings will be excluded from the study.
Comparison of Home-based Exercise Programmes for Falls Prevention and Quality of Life in Older Adults

This study compares the effects of three home-based exercise programmes in "at-risk to falling" older adults living in their own home on the incidence of falls (number and severity), risk factors, and quality of life as well as on the adherence to exercise. The subjects will be randomized and allocated in three groups. The group A will receive the "Test-and-Exercise" home-based programme (T\&E), the group B will receive the "Otago" home-based exercise programme and the group C (activ-control group) will receive the "Helsana" booklet

Home-based exercise programmes appear to reduce rate of falls, number of fallers, risk of falling and risk of death and to improve balance, leg strength, function, physical activity and balance confidence in older adults living in the community.

The Test-and-Exercise home-based programme (T\&E) contains 50 tests and 50 exercises to improve balance, strength and ability in older adults. It is especially built for older adults and is based on the concept of self-efficacy and empowerment. The originality of this programme is the evaluation of the difficulty perceived of the balance-exercises. It is delivered on a booklet which investigators had good experience with in our pilot study, with pictures and descriptions of each test and each exercise. Investigators also developed a mobile application. This application will be transmitted on a tablet-computer. In addition, the participants will receive cards with pictures of the exercises, to put into a plastic sheet to have an overview of their own exercise programme. This programme will be implemented from especially trained physiotherapists.

The Otago home-based exercise programme was developed in New-Zeeland in the 2000's to prevent falls in older adults. It proposes 22 exercises and walk training. The physiotherapists give an exercise prescription at each home visit. It shows good results for decrease falls in older adults, but the exercise adherence decrease also with the time.

The Otago home-based exercise programme was developed in New-Zeeland in the 2000's to prevent falls in older adults. It proposes 22 exercises and walk training. The physiotherapists give an exercise prescription at each home visit. It shows good results for decrease falls in older adults, but the exercise adherence decrease also with the time.

Eligibility Criteria:
Inclusion Criteria:

* 65 years old and older,
* Living in their own home,
* Having a history of fall in the previous 12 months or perceiving fear of falling (≥ 20 points on FES-I,
* Being able to walk without auxiliary tools in their home.
* Signed Informed Consent

Exclusion Criteria:

* Having severe vision impairment that do not permit the reading of the exercise-programme booklet and that do not permit the completing of the monthly diaries,
* Receiving physiotherapeutic treatment with balance learning,
* Having cognitive impairment (\<25 points on the Mini-Mental State Examination (MMSE) of Folstein
Maternal and Infant Cord Blood Monosaccharide Content

Mother's breast milk provides many benefits to babies with regard to development and improved health. We believe the simple sugars which make up these complex sugars in breast milk and are also found in the brain may be critical to normal brain development in term and preterm infants.

Babies are exposed to these sugars by placental transport during pregnancy and through mother's breast milk after they are born. For the preterm infant, we do not know if breast milk gives enough of these sugars compared to what the baby gets during pregnancy.

A maternal blood sample and blood samples from the baby's umbilical cord will provide us with background information for developing a supplement of special sugars that can be added to infant formulas to provide the amount that the baby usually gets during pregnancy and from breast milk.


Eligibility Criteria:
Inclusion Criteria:

* Healthy mothers with ages ranging from 18 to 35 yrs
* Delivered infants appropriate weight for gestational age (between 10% and 90%)

Exclusion Criteria:

* Maternal history of smoking, alcohol or drug use